Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Leukemia 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1High Risk Myeloid Malignancies 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 34fludarabine phosphate 33Cytarabine 33fludarabine 26Peripheral Blood Stem Cell Transplantation 23Filgrastim 23Methotrexate 18Busulfan 17Rituximab 15Cyclosporine 14Azacitidine 14Melphalan 13Clofarabine 13Tacrolimus 12venetoclax 11Mycophenolic Acid 10Etoposide 10Alemtuzumab 10Radiotherapy 9Imatinib Mesylate 8Granulocyte Colony-Stimulating Factor 8Decitabine 8ruxolitinib 7Whole-Body Irradiation 7Stem Cell Transplantation 7Idarubicin 7Dexamethasone 7Antilymphocyte Serum 7aldesleukin 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia × Transplantation Conditioning × Clear all
NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02053545 2019-08-30

Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡